ADC Therapeutics SA (ADCT) Stock

About ADC Therapeutics SA

ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.

ADC Therapeutics SA is led by CEO Ameet Mallik, employs 263 people, headquartered in CH, publicly traded since 2020.

ADC Therapeutics SA (ADCT) stock trades at $1.44 with a market capitalization of $183.84M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.14, reflecting a net loss over the last twelve months, a negative price-to-book of -0.96, reflecting negative shareholders' equity, price-to-sales of 2.29. Over the past 52 weeks the stock has ranged between $0.78 and $4.98, and currently trades 71.1% below its 52-week high.

On profitability, ADC Therapeutics SA generates a return on equity (ROE) of 44.63% (not meaningful, as shareholders' equity is negative), return on capital employed of -42.69%, an operating margin of -133.33%, a net profit margin of -123.03%.

Official website: www.adctherapeutics.com

ADC Therapeutics SA by the numbers, 2016–2025

Compounded, revenue has grown —% a year over five years, -27.2% over three, 14.1% over the last twelve months. Net profit was $-143.0M in 2025.

The most recent net margin is -123.03%. On a trailing twelve-month basis to Jun '26, revenue is $78.0M and net profit $-97.0M.

Borrowings stand at $439.0M, cash from operations was $-141.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -4.1% over five years, and was 76.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

ADC Therapeutics SA (ADCT) — frequently asked questions